# Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)

> **NCT05860881** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Melanoma and Skin Cancer Trials Limited** · enrollment: 146 (estimated)

## Conditions studied

- Solid Organ Transplant Recipients
- Skin Cancer

## Interventions

- **DRUG:** Sirolimus Topical Cream
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05860881
- **Lead sponsor:** Melanoma and Skin Cancer Trials Limited
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-09
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 146 (ESTIMATED)
- **Last updated:** 2025-09-09

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05860881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05860881, "Topical Sirolimus in Chemoprevention of Facial Squamous Cell Carcinomas in Solid Organ Transplant Recipients (SiroSkin)". Retrieved via AI Analytics 2026-07-27 from https://api.ai-analytics.org/clinical/NCT05860881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*